161 related articles for article (PubMed ID: 33453448)
1. The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study.
Cakir C; Kilic F; Kilic C; Tokgozoglu N; Ersak B; Ayhan S; Akar S; Yuksel D; Korkmaz V; Boran N; Toptas T; Kimyon Comert G; Ureyen I; Tasci T; Turkmen O; Moraloglu Tekin O; Ustun Y; Turan T
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102063. PubMed ID: 33453448
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study.
Unsal M; Kilic C; Cakir C; Kilic F; Ersak B; Karakas S; Tokgozoglu N; Varli B; Oktar O; Kimyon Comert G; Ozdemir IA; Boran N; Toptas T; Ureyen I; Korkmaz V; Taskin S; Moraloglu Tekin O; Ustun Y; Tasci T; Ortac F; Turan T
J Obstet Gynaecol; 2023 Dec; 43(1):2151355. PubMed ID: 36503383
[TBL] [Abstract][Full Text] [Related]
3. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
[TBL] [Abstract][Full Text] [Related]
4. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR
Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590
[TBL] [Abstract][Full Text] [Related]
6. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
7. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
8. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
9. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
[TBL] [Abstract][Full Text] [Related]
10. Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma.
Casarin J; Bogani G; Piovano E; Falcone F; Ferrari F; Odicino F; Puppo A; Bonfiglio F; Donadello N; Pinelli C; Laganà AS; Ditto A; Malzoni M; Greggi S; Raspagliesi F; Ghezzi F
J Gynecol Oncol; 2020 Sep; 31(5):e64. PubMed ID: 32808495
[TBL] [Abstract][Full Text] [Related]
11. Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center.
Ditto A; Leone Roberti Maggiore U; Lopez S; Martinelli F; Bogani G; Lo Vullo S; Brusadelli C; Paolini B; Ducceschi M; Mantiero M; Chiappa V; Signorelli M; Evangelista M; Mariani L; Raspagliesi F
Eur J Surg Oncol; 2022 Jan; 48(1):268-274. PubMed ID: 34753617
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
Vatansever D; Taskiran C; Mutlu Meydanli M; Gungorduk K; Akbayir O; Yalcin I; Demirkiran F; Sozen H; Ozgul N; Celik H; Onan MA; Taskin S; Oge T; Simsek T; Abboud S; Yuksel IT; Ayhan A
J Surg Oncol; 2021 May; 123(8):1801-1810. PubMed ID: 33657253
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis, treatment and prognosis of uterine serous carcinoma].
Zhang F; Deng LS; Li B; Huang MN; Li XG; Zhang R; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):848-856. PubMed ID: 33355760
[No Abstract] [Full Text] [Related]
14. Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma.
McEachron J; Zhou N; Hastings V; Bennett M; Gorelick C; Kanis MJ; Lee YC
Cancer Treat Res Commun; 2022; 33():100631. PubMed ID: 36096033
[TBL] [Abstract][Full Text] [Related]
15. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
17. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival.
Giuntoli RL; Gerardi MA; Yemelyanova AV; Ueda SM; Fleury AC; Diaz-Montes TP; Bristow RE
Int J Gynecol Cancer; 2012 Feb; 22(2):273-9. PubMed ID: 22146771
[TBL] [Abstract][Full Text] [Related]
18. Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.
Schiavone MB; Scelzo C; Straight C; Zhou Q; Alektiar KM; Makker V; Soslow RA; Iasonos A; Leitao MM; Abu-Rustum NR
Ann Surg Oncol; 2017 Jul; 24(7):1965-1971. PubMed ID: 28258415
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study.
Zhong X; Wang J; Kaku T; Wang Z; Li X; Wei L
Int J Gynecol Cancer; 2018 Jul; 28(6):1138-1144. PubMed ID: 29621127
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
